&nbsp;

Jan 2025

Drug

pegylated liposomal DOXOrubicin

Other Name(s): Caelyx®

Quick Link(s):

Sep 2025

Drug

PERTuzumab

Other Name(s): Perjeta®

Quick Link(s):

Sep 2022

Drug

pembrolizumab

Other Name(s): Keytruda®

Quick Link(s):

Sep 2025

Regimen

PGLDX

Cancer Type:

Gynecologic,

Ovary

Intent: Palliative

Funding:

New Drug Funding Program

Liposomal DOXOrubicin - Single Agent Treatment of Platinum Sensitive Ovarian Fallopian Tube or Primary Peritoneal Cancer

New Drug Funding Program

Liposomal Doxorubicin - Platinum-Resistant Ovarian Fallopian Tube or Primary Peritoneal Cancer

pegylated liposomal DOXOrubicin

Drugs Used:

Quick Link(s):

Regimen Monograph

Mar 2025

Regimen

PGLDX

Cancer Type:

Sarcoma,

Kaposi's Sarcoma

Intent: Palliative

Funding:

New Drug Funding Program

Liposomal Doxorubicin - HIV-positive Kaposi's Sarcoma

pegylated liposomal DOXOrubicin

Drugs Used:

Quick Link(s):

Regimen Monograph

Mar 2025

Regimen

PNTM

Cancer Type:

Gastrointestinal,

Colorectal,

Small bowel and appendix

Intent: Palliative

Funding:

New Drug Funding Program

Panitumumab - Metastatic Colorectal Small Bowel or Appendiceal Cancer

Drugs Used:

PANitumumab

Quick Link(s):

Regimen Monograph

Aug 2023

Regimen

PACL(W); PACL(W)+TRAS

Cancer Type:

Breast

Intent: Palliative

Funding:

New Drug Funding Program

Trastuzumab (Biosimilar) in combination with Chemotherapy - Metastatic Breast Cancer

New Drug Funding Program

Trastuzumab (Biosimilar) - Second Line - Metastatic Breast Cancer

Drugs Used:

PACLitaxel,

trastuzumab

Quick Link(s):

Regimen Monograph

May 2024

Regimen

PACL+PERT+TRAS

Cancer Type:

Breast

Intent: Palliative

Funding:

New Drug Funding Program

Pertuzumab with Trastuzumab (Biosimilar) - Unresectable Locally Recurrent or Metastatic Breast Cancer

New Drug Funding Program

Pertuzumab with Trastuzumab (Biosimilar) - Unresectable Locally Recurrent or Metastatic Breast Cancer

Drugs Used:

Quick Link(s):

Regimen Monograph

Sep 2022

Regimen

PACL(W)+TRAS

Cancer Type:

Breast

Intent: Adjuvant

Funding:

New Drug Funding Program

Trastuzumab (Biosimilar) - Adjuvant Treatment for Breast Cancer

Drugs Used:

PACLitaxel,

trastuzumab

Quick Link(s):

Regimen Monograph

Feb 2022

Regimen

PACL(W)+PERT+TRAS

Cancer Type:

Breast

Intent: Palliative

Funding:

New Drug Funding Program

Pertuzumab with Trastuzumab (Biosimilar) - Unresectable Locally Recurrent or Metastatic Breast Cancer

New Drug Funding Program

Pertuzumab with Trastuzumab (Biosimilar) - Unresectable Locally Recurrent or Metastatic Breast Cancer

Drugs Used:

Quick Link(s):

Regimen Monograph

Sep 2022

Regimen

PACLTOPO+BEVA

Cancer Type:

Gynecologic,

Cervix

Intent: Palliative

Funding:

New Drug Funding Program

Bevacizumab (Biosimilar) - Metastatic (Stage IVB), Persistent, or Recurrent Carcinoma of the Cervix

Drugs Used: